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Abstract
Background: Low-grade inflammation mediates the relation between overweight and the development of cardio-
vascular diseases. The study aimed to examine if myeloperoxidase (MPO) and hsCRP (high-sensitivity C-reactive 
protein) in overweight hypertensive patients can be used as biomarkers of endothelial and leukocyte activation. 
Material and methods: Seventy-five subjects were included in the study; 38 had essential arterial hypertension 
(AH) and 37 were normotensive controls (NC), subsequently divided into overweight (OW; BMI ≥ 25 kg/m2) and 
normal weight subgroups (NW; BMI < 25 kg/m2). Body mass index (BMI), inflammatory markers concentrations, 
association of MPO and hsCRP with AH and/or overweight were assessed. 
Results: AH patients had higher MPO (median 132.5 pmol/L, IQR: 53.8–691.9) (p < 0.001), while hsCRP did 
not significantly differ compared to normotensive controls (NC). NW-AH patients had higher MPO (p = 0.02) 
than normotensive NW patients. MPO was similar between normotensive patients OW and NW, while hsCRP 
concentration was significantly higher in the OW (median 1.85 mg/L, IQR: 0.47–7.19) (p = 0.01) compared to 
NW. OW-AH patients had significantly higher MPO (median 137.4 pmol/L, IQR: 53.80–703.4) (p = 0.002) com-
pared to normotensive NW and OW (p < 0.001) patients, likely reflecting neutrophilic activation in hypertension. 
Additionaly, OW-AH patients had significantly higher hsCRP (median 1.71 mg/L, IQR: 0.22–14) (p = 0.005) than 
normotensive NW patients. hsCRP significantly positively correlated with BMI in both AH (r = 0.41, p = 0,009) 
and NC groups (r = 0.38, p = 0.01), while MPO did not correlate, supporting inflammation in OW, particularly 
in OW with AH. 
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Introduction
Arterial hypertension (AH) is a major independent 
risk factor for development of cardiovascular (CV) 
diseases, such as heart failure and myocardial infarc-
tion, as well as the primary cause of stroke which 
makes it a significant public health problem [1]. 
Another CV risk factor and a global health epidemic 
is overweight (OW), a chronic disease with distinct 
metabolic and endocrine disorders, which result in 
a number of severe chronic complications [2]. The 
common denominator of the both, AH [3, 4] and 
overweight, is inflammation, which causes endothe-
lial dysfunction [5, 6] and has a key role in the devel-
opment and progression of atherosclerosis [7]. 
C-reactive protein (CRP) is an inflammatory 
biomarker synthesized in hepatocytes in response 
to primary stimulation by interleukin 6 (IL-6) [8]. 
A recent study demonstrated that high sensitive CRP 
(hsCRP) (which is a term for a more sensitive assay 
of CRP) is involved in mechanisms that lead to de-
velopment of AH [9]. hsCRP can be considered as 
biomarker of the process of endothelial dysfunction 
and, at supraphysiological concentrations, as a pre-
dictor of vascular disease [10]. 
Several studies have shown that CRP impaired 
endothelial vasoreactivity in vivo [11, 12] by inhibit-
ing endothelial nitric oxide synthase (eNOS) activity 
in vitro and in vivo, reducing NO availability, and 
by predisposing blood vessels to chronic vasospasm, 
leading to an increase in total vascular resistance 
and AH [13]. Interestingly, there are evidences that 
hsCRP may be also secreted by other cells than hepa-
tocytes, such as smooth muscle cells and adipocytes 
[14]. In addition, prolonged periods of low-grade 
systemic inflammation may explain the higher risk 
for high blood pressure observed among overweight 
people [15]. 
Myeloperoxidase (MPO) is a lysosomal enzyme 
present in neutrophils and monocytes, released dur-
ing their activation to the surface of vascular endo-
thelial cells and around them, following leukocyte 
degranulation [16]. MPO has affinity to both, the 
endothelial and the leukocyte’s surface and may con-
tribute to leukocytes attraction and recruitment to 
endothelial cells by its electrostatic effect of positively 
surface charge, which is a catalysis-independent func-
tion of the enzyme [17].
MPO catalyzes the production of hypochloric 
acid and a range of other highly reactive species. 
These MPO-derived reactive substances may dam-
age the arterial wall, thereby reducing its elasticity 
[18]. Another potentially important consequence of 
MPO activity is consumption of NO and induction 
of endothelial dysfunction [19].
MPO is rapidly taken up by endothelial cells by 
a transcytotic process and accumulates within the 
subendothelial space, positioning it anatomically to 
interfere with the effects of NO in the vessel wall 
[20]. Together, these mechanisms may lead to en-
dothelial dysfunction and subsequently increased 
blood pressure. And while some reports of studies 
in human subjects have shown a significant associa-
tion between blood pressure and hs-CRP elevation 
in people with hypertension [21, 22] other studies 
showed no significant relation between hypertension 
and hs-CRP [23, 24].
The aim of the study was to examine if myeloper-
oxidase (MPO) and hsCRP in overweight hyperten-
sive patients can be used as biomarkers of endothelial 
and leukocyte activation and their interaction.
Material and methods
The study included 75 examinees, 43 men and 32 
women, ranging in age from 20 to 70 years (median 
42). Thirty-eight patients were recently diagnosed 
having essential AH that lasted less than a year (AH 
stage 1 according to the European Hypertension 
Guidelines 2013 – systolic blood pressure ≥ 140 mm 
Hg and/or diastolic blood pressure ≥ 90 mm Hg), 
while 37 were normotensive controls. The study was 
designed as a cross-sectional investigation. The exam-
inees were recruited from the ambulatory office for 
nephrology and hypertension, in the Department of 
Nephrology, Osijek University Hospital, in Osijek, 
Croatia (Fig. 1). 
Conclusions: All together, the results suggest that inflammation may mediate mutual association of AH and OW, 
suggesting MPO as inflammatory biomarker for AH and hsCRP for overweight.
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Exclusion criteria were diabetes, liver disease, renal 
disease and/or serum creatinine above 97 µmol/L for 
men and 80 µmol/L for women, myocardial infarc-
tion, stroke and use of nonsteroidal anti-inflamma-
tory drugs or glucocorticoids.
The groups were further subdivided according to 
the body mass index (BMI) into an overweight (OW) 
group, with BMI ≥ 25 kg/m2, and a normal weight 
(NW) group, with BMI < 25 kg/m2. The studied 
groups’ characteristics are shown in the Table 1.
The previous workup for diagnosis of essential 
AH was as following: all patients were examined for 
medical history, then underwent physical examina-
tion that included arterial blood pressure measure-
ment using calibrated mercury sphygmomanometer 
with the suitable dimension cuff; blood pressure 
(BP) readings were taken while patients were in the 
sitting position and rested for 5 minutes; their BP 
was taken three times consecutively and the mean 
value was calculated for systolic and diastolic BP, 
respectively. The same procedure was performed 
in the controls group to exclude AH. During the 
study, the hypertensive patients did not receive an-
ti-hypertensive therapy for 2 weeks before the blood 
sampling. In patients with AH additional labo-
ratory tests were done to exclude secondary AH: 
plasma renin activity, aldosterone, metanephrine 
and normetanephrine in the 24-hour urine, ACTH, 
circadian rhythm cortisol, duplex sonography of 
the kidneys, endogenous creatinine clearance and 
24-hour proteinuria to assess renal function. Pa-
tients’ height and weight measurements were taken 
in the morning and the following laboratory tests 
were performed: total cholesterol, high density li-
poprotein (HDL), low density lipoprotein (LDL), 
triglycerides, plasma glucose, urea, creatinine, urate 
and urinalysis. All examinees were informed about 
the research methods, ethical principles and the 
purpose of the research prior to its beginning and 
they all gave their written informed consent.
MPO and hsCRP concentration measurements
Concentrations of MPO and hsCRP were de-
termined by aArchitect 1000i (ABBOT, United 
Figure 1. Formation of the sample in the study
Original sample 
(n = 120)
Met exclusion criteria 
(n = 15)
Postał questionnaire
Unwilling to participate 
(n = 8)
Did not meet exclusion criteria
(n = 105)
Declined to participate 
(n = 7)





















AH lasted more than a year
and/or conrmed secondary
AH — not included (n = 15)
AH lasted less than a year
and secondary
AH exclude (n = 38)
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States) analyzer in EDTA plasma, applying chemi-
luminescence microparticle immunoassay (CMIA). 
Serum hsCRP was determined using immunotur-
bidimetry test for quantitative determination on 
Olympus AU-680 analyzer (Beckman Coulter, 
Switzerland). 
Statistical analyses
The data were statistically analyzed by SPSS 15.0 
for Windows (SPSS Inc., Chicago, IL, USA). Cat-
egorical variables were expressed as proportions and 
percentages. Normality of distribution of numerical 
data was analyzed by Kolmogorov-Smirnov test. 
Differences in categorical variables were examined 
by chi-square test. Differences in numerical vari-
ables were tested by Student’s t-test for normally 
distributed variables and by Mann-Whitney test for 
nonparametric statistics. Binary logistic regression 
(Hosmer-Leveshow goodness of fit test) was used 
for multivariate analysis. Spearman’s r was deter-
mined for correlations between numeric variables. 
Values of p < 0.05 were considered statistically 
significant.
Results
Myeloperoxidase and hsCRP concentrations
Table 1 shows the general demographic character-
istics of the groups. The patients with AH were not 
different from normotensive individuals in age, gen-
der, plasma concentration of cholesterol and triglyc-
erides. AH patients had higher BMI (p = 0.001) 
and higher MPO concentrations (median 132.5 
pmol/L, 53.8–691.9) compared to the normoten-
sive group (NC) (median 73 pmol/L, 28.60–859.3) 
(p < 0.001). No difference in hsCRP concentrations 
were found between the two groups (p = 0.09).
Overweight hypertensive (OW-AH) and over-
weight normotensive (OW-NC) examinees together 
had higher hsCRP (median 1.8 mg/L, 0.22–14) 
(p = 0.01) compared to normal weight hypertensive 
(NW-AH) and normal weight normotensive (NW-
NC) examinees taken together (Tab. 2). MPO did 
not differ between all OW and all NW examinees.
MPO concentration and hsCRP concentration 
were not different in hypertensive OW patients 
compared to NW-AH patients (MPO p = 0.87 and 




AH (n = 38) NC (n = 37)
Age [yrs] 42 ± 14 (20–70) 40 ± 9 (24–55) t = 0.704 0.48
Sex (men/women) (n) 21/17 22/15 c² = 0.13 0.71
Cholesterol [mmol/L] 5.44 ± 1.05 5.55 ± 1.81 t = –0.33 0.74
HDL [mmol/L] 1.31 ± 0.34 1.4 ± 0.34 t = –0.86 0.39
LDL [mmol/L] 3.38 ± 1.03 3.35 ± 1.44 t =  0.10 0.92
Triglycerides [mmol/L] 1.38 (0.37–5.65) 1.62 (0.34–9.94) z = –0.81 0.42a
BMI [kg/m2] 27.97 (19.33–45.61) 25.2 (19.49–34.29) z = –3.38 0.001a
hsCRP [mg/L] 1.62 (0.22–14) 1.05 (0.13–7.19) z = –1.63 0.09a
MPO [pmol/L] 132.5 (53.8–691.9) 73 (28.6–859.3) z = –4.60 < 0.001a
HDL — high density lipoproteins; LDL — low density lipoproteins; BMI — body mass index; hsCRP — high-sensitivity C-reactive protein; MPO — myeloperoxidase; aMann-Whitney test
Table 2. Differences in high-sensitivity C-reactive protein (hsCRP) and myeloperoxidase (MPO) within the entire and within the hypertensive 
group according to body mass index (BMI)
BMI [kg/m2] z p
Entire group (n = 75) ≥ 25 (n = 48) < 25 (n = 27)
hsCRP [mg/L] 1.80 (0.22–14.00) 1.04 (0.13–5.50) –2.42 0.02a
MPO [pmol/L] 100.55 (28.6–703.40) 98.90 (30.8–859.3) –0.57 0.57
Hypertensive group (n = 38) ≥ 25 (n = 25) < 25 (n = 13)
hsCRP [mg/L] 1.71 (0.22–14.00) 1.55 (0.29–5.50) –0.49 0.62
MPO [pmol/L] 137.4 (53.80–703.4) 132.50 (37.75–691.90) 0.16 0.87
aMann-Whitney test
arterial hypertension 2021, vol. 25, no. 1
18 www.ah.viamedica.pl
tively correlated with BMI (for hsCRP correlation 
coefficient (r) = 0.44, p < 0.001; for MPO r = 0.24, 
p = 0.038).
hsCRP significantly positively correlated with 
BMI in hypertensive (n = 38, r = 0.42, p = 0.01) and 
in normotensive (n = 37, r = 0.39, p =0.01) groups 
respectively, while MPO did not correlate with BMI 
in any of these two groups (in the hypertensive group 
r = 0.18, p = 0.26, whereas in the normotensive 
group r = –0.12, p = 0.48). 
Discussion
The main findings of our study include: a) significant 
elevation of MPO concentration in hypertensive pa-
tients, irrespective of their BMI; b) significantly in-
creased hsCRP in overweight subjects, irrespective of 
AH; and c) hsCRP significantly positively correlates 
with BMI in all participants, irrespective of AH. 
Nevertheless, MPO and hsCRP were significantly 
increased at the same time only in patients who were 
both hypertensive and overweight compared to the 
normotensive overweight and normal weight sub-
jects. Our results are in concordance with the data 
obtained in study by Heine et al. [25] in which the 
concentrations of MPO in the circulation positively 
associated with systolic and diastolic blood pressure, 
and in concordance with the data obtained in study 
by Yudkin et al. [26] which showed relationships 
between levels of CRP and measures of overweight 
in healthy subjects without hypertension.
hsCRP p = 0.61, respectively) (Tab. 2). OW normo-
tensive subjects did not significantly differ from NW 
normotensive subjects in MPO concentrations (me-
dian 73 pmol/L, 28.60–131.50 in OW compared 
to median 78.05 pmol/L, 30.80–859.30 in NW) 
(p = 0.56), while significantly higher concentrations 
of hsCRP were found in overweight normotensive 
subjects (OW-NC) (median 1.85 mg/L, 0.47–7.19 
compared to median 0.89 mg/L, 0.13–4.64 in NW) 
(p = 0.01).
OW-AH patients had significantly higher MPO 
(median 137.4 pmol/L, 53.8–703.4) (p = 0.002) and 
hsCRP (median 1.71 mg/L, 0.22–14) (p = 0.005) 
compared to NW-NC patients. OW-AH patients 
had significantly higher MPO compared to normo-
tensive OW subjects (p < 0.001), while hsCRP did 
not differ between those two OW subgroups (p = 
0.72) (Tab. 3). 
Multivariate analysis 
Multivariate analysis (binary logistic regression) with 
overweight, hsCRP and MPO as covariates showed 
that overweight was independently significantly pre-
dictive for AH, unlike hsCRP, while higher MPO 
increased risk for AH with statistically marginal sig-
nificance (Tab. 4).
Correlations between MPO and hsCRP
Within the entire examined group (n = 75) Spear-
man Rank Correlation Analysis of body mass index 
(BMI, kg/m²) with serum concentrations of hsCRP 
and with MPO showed that hsCRP and MPO posi-
Table 3. Differences in myeloperoxidase (MPO) and high sensitivity C-reactive protein (hsCRP) between arterial hypertension (AH) patients 
and normotensive controls (NC) divided  according to body mass index (BMI)
BMI [kg/m2] MPO [pmol/L] z p
AH (n = 38) NC (n = 37)
< 25 132.5 (37.75–691.9)*† 78.5 (30.8–59.3)*‡ *–2.21, 0.03a
≥ 25 137.4 (53.8–703.4)‡§ 73 (28.6–131.5)†§ § –4.04, < 0.001a
hsCRP [mg/L]
AH (n = 38) NC (n = 37)
< 25 1.55 (0.29–5.5)*† 0.89 (0.13–4.64)*‡ *–1.42 0.15
≥ 25 1.71 (0.22–14)‡ § 1.85 (0.47–7.19)†§ § –0.34 0.73
aMann Whitney test; MPO: †z = –0.64, p = 0.008; ‡z = –3.15, p = 0.002; hsCRP: †z = –0.566, p = 0.572, ‡z = 2.778, p = 0.005
Table 4. Binary logistic regression (Hosmer-Lemeshow goodness of fit test) for arterial hypertension (n = 38) as dependent variable (n = 75)
Covariate p Exp (B) 95%CI
Obesity 0.044 3.00 1.03–8.75
hsCRP [mg/L] 0.247 1.19 0.88–1.61
MPO [pmol/L] 0.069 1.00 1–1.01
hsCRP — high-sensitivity C-reactive protein; MPO — myeloperoxidase; CI — confidence interval
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Our results suggest that hypertensive patients 
might have higher neutrophil activation than nor-
motensive subjects, reflected by MPO increase, and 
also suggest potential role of inflammation in the 
development of AH, by MPO affecting the local 
vascular level of oxidative stress, thus possibly alter-
ing the synthesis and degradation of vasodilating and 
vasoconstricting factors, as discussed in [27]. 
Previous studies confirmed that inflammatory 
process is an integral part of AH by showing elevated 
concentration of CRP in hypertensive patients [28]. 
Moreover, it has been suggested that elevated CRP 
in healthy humans lead to an increased risk of de-
veloping AH [29]. CRP in arterial wall promotes 
expression of adhesion molecules E-selectin, cell ad-
hesion molecules wall 1 (VCAM-1) and intercellular 
adhesion molecule1 (ICAM-1) on endothelial cells. 
Dysfunction of endothelial cells, as induced by CRP, 
renders reduced NO synthesis, resulting in enhanced 
reactivity of blood vessel wall [30]. 
Overweight per se is a condition of chronic inflam-
mation which could contribute to a further endo-
thelial damage, worsening the vascular disease and 
promoting development or maintenance of AH [31]. 
Thus, one of the goals of the present study was to 
evaluate the potential mutual interaction of over-
weight and hypertension.
Plasma concentration of hsCRP has been shown 
to be strongly associated with OW and OW-related 
diseases, including diabetes mellitus, and hyperlip-
idemia [31]. In the present study, overweight hy-
pertensive and normotensive patients together had 
significantly increased hsCRP, which is in accordance 
with the literature [31, 32]. Moreover, there was 
a significant positive correlation between the con-
centrations of hsCRP and BMI within the entire 
examined group. All together, these findings sup-
port hypothesis that hsCRP is a good marker of 
overweight-associated inflammation, independently 
of the blood pressure.  
Although there was a positive correlation between 
hsCRP and BMI in the group of hypertensive pa-
tients, there was no difference in hsCRP levels be-
tween OW and NW-AH patients. In support of 
this, the results of The Relationship between Blood 
Pressure and C-Reactive Protein in the Multi-Ethnic 
Study of Atherosclerosis (MESA) study [33] dem-
onstrated that some hypertensive groups showed 
a greater association, while some groups showed no 
difference in CRP in respect with the hypertension 
status. MESA showed that Chinese participants had 
the lowest CRP concentration but the largest dif-
ference in CRP by hypertension status, followed by 
Caucasians and African Americans, whereas Hispan-
ics had no significant difference in CRP by hyperten-
sion status. It might be that some other factors, be-
sides being OW, affect the value of CRP in AH. Nev-
ertheless, the level of systemic inflammatory markers 
such as CRP, white blood cell count and albumin are 
at least partially determined by genetic factors [34].    
Adipose tissue has been characterized as a dy-
namic endocrine organ that produces proinflamma-
tory cytokines. Overweight is a well-known predictor 
of AH and may confound the association between 
inflammation and hypertension [35]. However, the 
finding that hsCRP statistically significantly posi-
tively correlated with BMI in normotensive patients 
might support a previously published research which 
found that the protein may be released by adipocytes. 
Our data also showed a positive correlation between 
hsCRP and BMI in normotensive group. Therefore, 
it can be concluded that overweight, as a chronic 
persistent process, affects CRP levels, thus increasing 
the risk of developing CV disease in normotensive 
participants, i.e. independently of AH. In support 
of this thesis is large prospective epidemiological 
study that have shown that plasma level of hsCRP 
was a strong independent risk for a future myocar-
dial infarction, stroke, peripheral arterial disease and 
vascular death among individuals without known 
previous CV disease [36]. 
While concentration of MPO activity was found 
significantly elevated in hypertensive patients in 
comparison with the normotensive, regardless of 
BMI, high-sensitivity C-reactive protein between 
those groups were different only in respect to BMI. 
That means that only OW-AH patients had sig-
nificantly higher hsCRP compared to the NW-
normotensive subjects, while hsCRP did not differ 
between OW-AH patients and OW-normotensive 
subject, suggesting that the association between 
hsCRP and OB could be stronger in hypertensive 
individuals, which makes it more difficult to dis-
tinguish independent effects of inflammation or 
overweight on AH.
Our results showed a positive correlation between 
BMI and hsCRP in hypertensive and normotensive 
patients, but with no impact on MPO, suggesting 
that the increase in body weight induces endothelial 
inflammation processes, which may contribute to the 
development of hypertension.
Taken together, the results of our study lead to the 
conclusion that the effect of hsCRP and MPO in the 
development of AH might be strengthened by the 
increase in body weight, due to the observed fact that 
only patients who are hypertensive and overweight 
at the same time had significantly increased both 
hsCRP and MPO compared to all normotensive 
arterial hypertension 2021, vol. 25, no. 1
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subjects, regardless of their BMI. Additionally, the 
findings could reflect that overweight might partici-
pate in the development of AH due to the proinflam-
matory processes.
Conclusion
In the present study, MPO was significantly higher 
in patients with AH, irrespectively of BMI, which 
indicates neutrophilic activation concomitant to hy-
pertension. OW is associated with proinflammatory 
effects, as evident by increase in hsCRP in OW par-
ticipants (both hypertensive and normotensive), but 
without effect on leukocyte activations in any of the 
studied groups. Only in patients with both hyperten-
sion and overweight, there were significantly higher 
concentrations of MPO and hsCRP compared to 
the healthy normal weight subjects who had either 
AH or OW solely. Taken together, our data provide 
evidence that inflammation may be an important 
link between overweight and AH and that MPO and 
hsCRP may serve as good markers for inflammatory 
processes common to these two diseases. Altogether, 
results suggest that inflammation may mediate mu-
tual association of AH and OW, suggesting MPO 
as an inflammatory marker for AH and hsCRP for 
overweight. 
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References
1. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies 
Collaboration. Age-specific relevance of usual blood pressure to 
vascular mortality: a meta-analysis of individual data for one mil-
lion adults in 61 prospective studies. Lancet. 2002; 360(9349): 
1903–1913, doi: 10.1016/s0140-6736(02)11911-8, indexed in 
Pubmed: 12493255.
2. Jelaković B, Željković-Vrkić T, Pećin I, et al. Arterijska hiperten-
zija u Hrvatskoj.Rezultati EH-UH studije. Acta Med Croatica. 
2007; 61: 287–92.
3. Boos CJ, Lip GYH. Is hypertension an inflammatory process? 
Curr Pharm Des. 2006; 12(13): 1623–1635, doi: 10.2174/138
161206776843313, indexed in Pubmed: 16729874.
4. Kakar P, Lip GYH. Towards understanding the aetiology and 
pathophysiology of human hypertension: where are we now? 
J Hum Hypertens. 2006; 20(11): 833–836, doi:  10.1038/
sj.jhh.1002082, indexed in Pubmed: 16929340.
5. Sinisalo J, Paronen J, Mattila KJ, et al. Relation of inflamma-
tion to vascular function in patients with coronary heart disease. 
Atherosclerosis. 2000; 149(2): 403–411, doi:  10.1016/s0021-
9150(99)00333-0, indexed in Pubmed: 10729391.
6. Schwedler SB, Kuhlencordt PJ, Ponnuswamy PP, et al. Native 
C-reactive protein induces endothelial dysfunction in ApoE-
/- mice: implications for iNOS and reactive oxygen species. 
Atherosclerosis. 2007; 195(2): e76–e84, doi: 10.1016/j.athero-
sclerosis.2007.06.013, indexed in Pubmed: 17669410.
7. Libby P. Inflammation in atherosclerosis. Nature. 2002; 
420(6917): 868–874, doi:  10.1038/nature01323, indexed in 
Pubmed: 12490960.
8. Steffel J, Lüscher TF. Predicting the development of atheroscle-
rosis. Circulation. 2009; 119(7): 919–921, doi: 10.1161/CIR-
CULATIONAHA.108.846725, indexed in Pubmed: 19237671.
9. Kim JS, Kang TS, Kim JB, et al. Significant association of C-
reactive protein with arterial stiffness in treated non-diabetic 
hypertensive patients. Atherosclerosis. 2007; 192(2): 401–406, 
doi:  10.1016/j.atherosclerosis.2006.05.025, indexed in 
Pubmed: 16782104.
10. Souza JR, Oliveira RT, Blotta MH, et al. Serum levels of inter-
leukin-6 (Il-6), interleukin-18 (Il-18) and C-reactive protein 
(CRP) in patients with type-2 diabetes and acute coronary 
syndrome without ST-segment elevation. Arq Bras Cardiol. 
2008; 90(2): 86–90, doi: 10.1590/s0066-782x2008000200004, 
indexed in Pubmed: 18392379.
11. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that 
C-reactive protein decreases eNOS expression and bioactivity 
in human aortic endothelial cells. Circulation. 2002; 106(12): 
1439–1441, doi: 10.1161/01.cir.0000033116.22237.f9, indexed 
in Pubmed: 12234944.
12. Hein TW, Singh U, Vasquez-Vivar J, et al. Human C-reactive 
protein induces endothelial dysfunction and uncoupling of eNOS 
in vivo. Atherosclerosis. 2009; 206(1): 61–68, doi: 10.1016/j.
atherosclerosis.2009.02.002, indexed in Pubmed: 19268941.
13. Guan H, Wang P, Hui R, et al. Adeno-associated virus-mediated 
human C-reactive protein gene delivery causes endothelial 
dysfunction and hypertension in rats. Clin Chem. 2009; 55(2): 
274–284, doi:  10.1373/clinchem.2008.115857, indexed in 
Pubmed: 19056836.
14. Calabro P, Chang DW, Willerson JT, et al. Release of C-reactive 
protein in response to inflammatory cytokines by human adi-
pocytes: linking obesity to vascular inflammation. J Am Coll Car-
diol. 2005; 46(6): 1112–1113, doi: 10.1016/j.jacc.2005.06.017, 
indexed in Pubmed: 16168299.
15. Mendall MA, Patel P, Ballam L, et al. C reactive protein and its 
relation to cardiovascular risk factors: a population based cross sec-
tional study. BMJ. 1996; 312(7038): 1061–1065, doi: 10.1136/
bmj.312.7038.1061, indexed in Pubmed: 8616412.
16. Norman PE, Powell JT. Vitamin D, shedding light on the 
development of disease in peripheral arteries. Arterioscler 
Thromb Vasc Biol. 2005; 25(1): 39–46, doi:  10.1161/01.
ATV.0000148450.56697.4a, indexed in Pubmed: 15499037.
17. Klinke A, Nussbaum C, Kubala L, et al. Myeloperoxidase at-
tracts neutrophils by physical forces. Blood. 2011; 117(4): 
1350–1358, doi: 10.1182/blood-2010-05-284513, indexed in 
Pubmed: 20980678.
18. Schindhelm RK, van der Zwan LP, Teerlink T, et al. Myeloper-
oxidase: a useful biomarker for cardiovascular disease risk strati-
fication? Clin Chem. 2009; 55(8): 1462–1470, doi: 10.1373/
clinchem.2009.126029, indexed in Pubmed: 19556446.
19. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological sub-
strate for mammalian peroxidases. J Biol Chem. 2000; 275(48): 
37524–37532, doi:  10.1074/jbc.275.48.37524, indexed in 
Pubmed: 11090610.
20. Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, 
a leukocyte-derived vascular NO oxidase. Science. 2002; 
296(5577): 2391–2394, doi: 10.1126/science.1106830, indexed 
in Pubmed: 12089442.
Dunja Buljubasic et al. Inflammation in overweight hypertensive patients
21www.ah.viamedica.pl
21. Sung KC. High sensitivity C-reactive protein as an independent 
risk factor for essential hypertension. Am J Hypertens. 2003; 
16(6): 429–433, doi: 10.1016/s0895-7061(03)00566-1, indexed 
in Pubmed: 2799089.
22. Bautista LE, López-Jaramillo P, Vera LM, et al. Is C-reactive 
protein an independent risk factor for essential hypertension? 
J Hypertens. 2001; 19(5): 857–861, doi: 10.1097/00004872-
200105000-00004, indexed in Pubmed: 11393667.
23. Shafi Dar M, Pandith AA, Sameer AS, et al. hs-CRP: A potential 
marker for hypertension in Kashmiri population. Indian J Clin 
Biochem. 2010; 25(2): 208–212, doi:  10.1007/s12291-010-
0037-7, indexed in Pubmed: 23105911.
24. Bautista LE, Vera LM, Arenas IA, et al. Independent association 
between inflammatory markers (C-reactive protein, interleukin-6, 
and TNF-alpha) and essential hypertension. J Hum Hypertens. 
2005; 19(2): 149–154, doi:  10.1038/sj.jhh.1001785, indexed 
in Pubmed: 15361891.
25. Van der Zwan LP, Scheffer PG, Dekker JM, et al. Hyperglyc-
emia and oxidative stress strengthen the association between 
myeloperoxidase and blood pressure. Hypertension. 2010; 55(6): 
1366–1372, doi: 10.1161/HYPERTENSIONAHA.109.147231, 
indexed in Pubmed: 20385972.
26. Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive protein 
in healthy subjects: associations with obesity, insulin resistance, 
and endothelial dysfunction: a potential role for cytokines 
originating from adipose tissue? Arterioscler Thromb Vasc Biol. 
1999; 19(4): 972–978, doi: 10.1161/01.atv.19.4.972, indexed 
in Pubmed: 10195925.
27. Hingorani AD, Cross J, Kharbanda RK, et al. Acute systemic 
inflammation impairs endothelium-dependent dilatation in 
humans. Circulation. 2000; 102(9): 994–999, doi: 10.1161/01.
cir.102.9.994, indexed in Pubmed: 10961963.
28. Bautista LE, Atwood JE, O’Malley PG, et al. Association between 
C-reactive protein and hypertension in healthy middle-aged 
men and women. Coron Artery Dis. 2004; 15(6): 331–336, 
doi:  10.1097/00019501-200409000-00006, indexed in 
Pubmed: 15346091.
29. Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk 
of developing hypertension. JAMA. 2003; 290(22): 2945–2951, 
doi: 10.1001/jama.290.22.2945, indexed in Pubmed: 14665655.
30. Fabijanić D, Banić M, Kardum D. C-reaktivni protein u procjeni 
kardiovaskularnog rizika. Liječ Vjesn. 2006; 128: 167–74.
31. Hak AE, Stehouwer CD, Bots ML, et al. Associations of C-
reactive protein with measures of obesity, insulin resistance, 
and subclinical atherosclerosis in healthy, middle-aged women. 
Arterioscler Thromb Vasc Biol. 1999; 19(8): 1986–1991, 
doi: 10.1161/01.atv.19.8.1986, indexed in Pubmed: 10446082.
32. Mitu F, Rezuş E, Banu C, et al. Inflammatory markers in hyper-
tensive patients and influence of some associated metabolic risk 
factor. Rev Med Chir Soc Med Nat Iasi. 2014; 118(3): 631–636, 
indexed in Pubmed: 25341276.
33. Lakoski SG, Cushman M, Siscovick DS, et al. The relationship 
between blood pressure and C-reactive protein in the Multi-
Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 
2005; 46(10): 1869–1874, doi:  10.1016/j.jacc.2005.07.050, 
indexed in Pubmed: 16286174.
34. Pankow J, Folsom A, Cushman M, et al. Familial and ge-
netic determinants of systemic markers of inflammation: the 
NHLBI family heart study. Atherosclerosis. 2001; 154(3): 
681–689, doi:  10.1016/s0021-9150(00)00586-4, indexed in 
Pubmed: 11257270.
35. Sonnenberg GE, Krakower GR, Kissebah AH. A novel path-
way to the manifestations of metabolic syndrome. Obes Res. 
2004; 12(2): 180–186, doi: 10.1038/oby.2004.24, indexed in 
Pubmed: 14981209.
36. Ridker PM. High-sensitivity C-reactive protein: potential 
adjunct for global risk assessment in the primary preven-
tion of cardiovascular disease. Circulation. 2001; 103(13): 
1813–1818, doi:  10.1161/01.cir.103.13.1813, indexed in 
Pubmed: 11282915.
